Last reviewed · How we verify
NCT05563987: ACT-DE
ACT-DE for Diabetes Distress in Adults With Type 2 Diabetes: A Pilot RCT
NA trial testing ACT-DE in Acceptance and Commitment Therapy in 48 participants. Completed in 30 March 2022.
28 February 2022
Quick facts
| Lead sponsor | Chinese University of Hong Kong |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 48 |
| Start date | 1 October 2021 |
| Primary completion | 28 February 2022 |
| Estimated completion | 30 March 2022 |
| Sites | 1 location across Hong Kong |
Drugs / interventions tested
- ACT-DE
- DE
Conditions studied
- Acceptance and Commitment Therapy — all drugs for Acceptance and Commitment Therapy →
- Type 2 Diabetes — all drugs for Type 2 Diabetes →
- Diabetes Distress — all drugs for Diabetes Distress →
Sponsor
Chinese University of Hong Kong
Who can join
Adults 18 to 64, any sex, with Acceptance and Commitment Therapy or Type 2 Diabetes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a pilot RCT to examine the feasibility, acceptability and preliminary effectiveness of a 6-week acceptance-based diabetes education programme (ACT-DE) on diabetes distress, self-care efficacy and behaviours of adults with type 2 diabetes in Hong Kong. It is hypothesise that the ACT-DE programme will: * Be acceptable, feasible and beneficial for adults with type 2 diabetes to improve their psychological distress and self-care. * Significantly reduce participants' diabetes distress (primary outcomes), when compared with the usual care (control) group immediately post-intervention; * Significantly improve self-care efficacy, self-care behaviour and psychological flexibility (secondary outcomes) than the control group immediately post-intervention.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05563987
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of ACT-DE
Trials testing the same drug.
- NCT05584085 — ACT-DE for Diabetes Distress and HbA1c in Adults With Type 2 Diabetes · NA · unknown
Other recruiting trials for Acceptance and Commitment Therapy
Currently open trials in the same condition.
- NCT07512388 — Acceptance and Commitment Therapy for Post-Stroke Adjustment Via Telerehabilitation · NA · active not recruiting
- NCT07033832 — Acceptance and Commitment Therapy-based Intervention for Parents of a Child With Medical Complexity · NA · recruiting
- NCT06971861 — Just ACT for Student Well-being · NA · recruiting
- NCT06457178 — Investigation of the Effect of Acceptance and Commitment Therapy-Based Intervention in Oncology Patients · NA · recruiting
- NCT06789926 — The Impact of Multimedia Psychological Support Platform and Acceptance and Commitment Therapy Workshops of Oncology Nurs · NA · recruiting
Other Chinese University of Hong Kong trials
Trials by the same sponsor.
- NCT07508644 — RSV Vaccination to Reduce Recurrent AECOPD · Phase 4 · not yet recruiting
- NCT07230457 — Plasma MTB cfDNA Before Bronchoscopy · not yet recruiting
- NCT07288671 — Nostalgia Intervention on Alleviating Loneliness Amongst Older Adults · NA · not yet recruiting
- NCT07256457 — Postoperative Pulmonary Function Assessment Based on Deep Learning Study · NA · not yet recruiting
- NCT06904209 — Can Artificial Intelligence Reduce Consumption of Standard High Volume Bowel Preparation Regimen Among Older Population, · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05563987 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chinese University of Hong Kong
- Last refreshed: 4 October 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05563987.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing